Real-World Trial Points to a Winner in Severe Heme A

Real-world findings from more than 200 patients treated with either recombinant FVIII Fc fusion protein (rFVIIIFc; Eloctate, Bioverativ) or rFVIII is bolstering a body of evidence showing rFVIIIFc is more effective in reducing bleeding rates in patients with severe hemophilia.

Source link